DLBCL News Briefs

DNA

Circulating Tumor DNA Clearance May Be a Biomarker in DLBCL

Early clearance of circulating tumor DNA (ctDNA) could potentially serve as a biomarker for patients with diffuse large B-cell lymphoma (DLBCL) receiving first-line therapy, according to a recently published study in the journal Blood. Although the introduction of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) immunochemotherapy has significantly improved prognosis in patients with DLBCL, approximately 30%…

Clinical Trial

Patient Baseline Characteristics May Impact Outcomes in DLBCL Trials

Patient baseline characteristics such as age, International Prognostic Index (IPI), and tumor stage may significantly impact the variability in efficacy observed in clinical trials assessing systemic therapy for diffuse large B-cell lymphoma (DLBCL), according to a study recently published in the Journal of Comparative Effectiveness Research.  Currently, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) immuno-chemotherapy…

medication

Trial Set to Evaluate Efficacy of Combined Therapy for Resistant DLBCL

A new clinical trial aims to assess the efficacy, safety, and tolerability of combined therapy with PF-07901801, tafasitamab, and lenalidomide in the management of patients with relapsing or refractory diffuse large B-cell lymphoma (DLBCL). The trial is currently in the recruitment phase. The multicenter, open-label, phase 1b/2 study aims to enroll approximately 70 patients with…

prescription pad

Novel Therapeutic Cocktail Appears Well-Tolerated in DLBCL

The addition of carfilzomib to rituximab, ifosfamide, carboplatin, and etoposide phosphate (R-ICE) is well-tolerated. The therapeutic cocktail leads to a high response rate, especially in patients with nongerminal center B-cell-like (nonGCB) diffuse large B-cell lymphoma (DLBCL), according to a new study published in the journal Blood Advances.  Patients with refractory DLBCL or those whose disease…

medicine bag

Intravenous Methotrexate More Effective Than Intrathecal Methotrexate in DLBCL

Prophylactic treatments containing high-dose intravenous methotrexate are better than those consisting of intrathecal methotrexate or no prophylaxis at all in preventing the central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) in intermediate-to-high-risk patients. This is according to a new study by Chinese researchers published in the journal International Immunopharmacology.  Intrathecal and high-dose…

cancer cells

Select Cytokines May Be Linked With Poor Prognosis in DLBCL

T-cell immunoglobulin mucin molecule-3 (Tim-3), transforming growth factor β (TGF-β), and chemokine-12 (CXCL12), tend to be highly expressed in diffuse large B-cell lymphoma (DLBCL) tissues and could be correlated with a poorer prognosis, according to a recently published study in World Journal of Clinical Cases. Despite the introduction of new treatment lines for DLBCL in…

Diffuse Large B-Cell Lymphoma Etiology

CD3 Cell Count May Predict CAR T-Cell Therapy Response in DLBCL

CD3 cell count at the moment of leukapheresis could predict response to chimeric antigen receptor (CAR) T-cell therapy in patients with diffuse large B-cell lymphoma (DLBCL), thus aiding the development of therapeutic strategies, according to a recently published study in Scientific Reports. Although DLBCL is curable with chemotherapy regimens based on anthracycline, an important percentage of…

medicine bag

CAR T-Cell Therapy May Be Effective in Relapsed and Refractory DLBCL

Treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are in complete remission at the time of infusion with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is feasible, safe, and associated with favorable disease control, according to a new study published in the journal Blood Advances. However, “further exploration in a larger clinical trial…

Prescription Medications

Lenalidomide and Obinutuzumab Appear to Be Effective in DLBCL Care

Immunochemotherapy combining lenalidomide and obinutuzumab with cyclophosphamide, doxorubicin, vincristine, and prednisone (LO-CHOP) appears to have high efficacy in the treatment of newly diagnosed diffuse large B-cell lymphoma (DLBCL), according to a recently published study in Blood Advances. Currently, the immunochemotherapy regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) constitutes the mainstay of therapy for patients…

Next post in DLBCL News Briefs